RxDoctor Payments Data

Lisa Swize, MD

Gastroenterology · Englewood, CONPI 1376680637

Payments from drug & device makers

$5,513in general payments, 2019–2025

Across 236 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$671
  • Gilead$288
  • Johnson & Johnson$255
  • Sanofi$253
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$244
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$5,496100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,513 in reported general payments places this provider in the 65th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$76,865
Medicare patients
269
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$83,754
XeljanzTofacitinib Citrate12$65,706
XifaxanRifaximin19$41,872
LinzessLinaclotide15$20,415
SutabSod Sulf/Pot Chloride/Mag Sulf109$18,031
Mesalamine ErMesalamine27$7,503
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag18$2,255
CholestyramineCholestyramine (With Sugar)21$1,957
Omeprazole134$1,952
Famotidine99$1,778
Budesonide DrBudesonide19$1,620
Ursodiol11$909
Dicyclomine Hcl24$533
Pantoprazole Sodium40$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$155$65,70612 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$244$41,87219 claims
AbbVieLinzess$2,152$20,41515 claims
Braintree Laboratories, Inc.Sutab, Suflave$13$20,286127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →